Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.34 |
| ▸ | ABAT | P80404 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4952546 | 0.78 | CYP3A4 (0.50) | PTGS1HSD17B10KIF11ALDH1A1KDM4E | |
| SCHEMBL4948064 | 0.77 | PTGS1 (0.50) | PTGS1CYP2A6DRD1HSD17B10ALDH5A1 | |
| SCHEMBL15332349 | 0.76 | PTGS1 (0.56) | PTGS1CYP2A6DRD1HSD17B10ALDH5A1 | |
| SCHEMBL5963985 | 0.76 | PTGS1 (0.56) | PTGS1CYP2A6ALDH1A1TYRCYP2A13 | |
| SCHEMBL4951483 | 0.73 | MAP4K4 (0.41) | PTGS1HSD17B10KIF11ALDH1A1KDM4E | |
| SCHEMBL4375211 | 0.73 | PTGS1 (0.53) | PTGS1CYP2A6DRD1HSD17B10ALDH5A1 | |
| SCHEMBL8289756 | 0.72 | PTGS1 (0.31) | PTGS1PTGS2 | |
| SCHEMBL3128189 | 0.72 | MAPT (0.41) | CYP2A6ALDH1A1 | |
| SCHEMBL7457943 | 0.72 | CASP3 (0.41) | CYP2A6HSD17B10ALDH1A1KDM4EPTGS2 | |
| SCHEMBL4197618 | 0.72 | MAPK14 (0.50) | PTGS1HSD17B10ALDH1A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893597-B1 | AMPA RECEPTOR POTENTIATORS | LILLY CO ELI (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7393868-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1893597-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142441-A1 | AMPA receptor potentiators | ELI LILLY AND COMPANY | 2007-06-21 | — | — | US | disclosed |
| WO-2006132811-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142441-A1 | AMPA receptor potentiators | GABRE, GRIN1, GRIK2 | PTGS1 1216/4885CYP2A6 2442/4885DRD1 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.